BENZALIP

Dose: 200 mg
Single Dose: 200 (200)
Frequency: 8 hourly
Route: PO
Instructions: With or after food.

Dose:
Single Dose:
Frequency:
Route:
Instructions: Not recommended in this age group

. It is of Synthetic origin and belongs to Priopionic Acid. It belongs to Lipid lowering agents pharmacological group on the basis of mechanism of action. The Molecular Weight of Bezafibrate is 361.80. Its pKa is 3.61.

Bezafibrate is contraindicated in conditions like Renal failure,Liver cirrhosis,Nephrotic syndrome,Hypoalbuminaemia.

The symptomatic adverse reactions produced by Bezafibrate are more or less tolerable and if they become severe, they can be treated symptomatically, these include Nausea, GI distention, Myositic syndrome.

Bezafibrate is primarily indicated in conditions like Hypercholesterolaemia, Prophylaxis of NSAID-associated gastric or duodenal ulcer.

Bezafibrate is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementCerivastatin SodiumCerivastatin sodium causes additive toxicity with BezafibrateFluvastatinIncreased risk of myopathy when fibrates (e.g Bezafibrate) given with statins (e.g Fluvastatin). These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Drug should not be given to Pregnant Mothers, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Tab Store in a well closed container, Below 40°C.

Bezafibrate should not be given to patients with severe liver or kidney impairment, primary biliary cirrhosis, gallstone or gallbladder disorder or hypoalbuminaemic state.